The Federal Agency for Medicines and Health Products (FAMHP) is holding a symposium on vaccines on Friday 6 December 2019. The symposium will highlight certain current challenges in the development of new vaccines and the improvement of existing vaccines. Spekers will also talk about the role of various Belgian public institutions in bringing vaccines to market and monitoring them.
How can public health authorities such as the FAMHP, in cooperation with the FPS Public Health, the RIZIV-INAMI and the KCE, involve the patient more proactively and make the patient more central through the entire development cycle of innovative drugs? Come and find out everything at the third symposium of the FAMHP, where patients are central, on Tuesday, December 10.
Europe has approved new legislation on veterinary medicines and medicated animal feeds. What does this mean and what will change concretely for the industry or veterinarian?
Good distribution practices of medicinal products : update of questions and answers regarding GDP legislation
The FAMHP Distribution division updates the list of questions and answers on rules of Good Distribution Practices (GDP) of medicinal products for human use.
The FAMHP was confronted with a case of identity theft whereby company details where abused for the illegal obtention of drug precursors.
European Commission on the lookout for experts on medical devices and in-vitro diagnostic medical devices
These experts will form panels, providing advice and evaluating new devices that present a risk.
Brexit is coming very shortly. And it will have great consequences for many Belgian companies.
A nitrosamine impurity (NDMA, N-nitrosodimethylamine) has been detected in medicines based on ranitidine. The European Medicines Agency (EMA) has started a review. As a precautionary measure, the companies involved are recalling the medicine or placing the medicines in quarantine.
On Tuesday, October 15, 2019, the Vigilance Division of the Federal Agency for Medicines and Health Products (FAMHP) is organising a Vigilance Day in Brussels for the sixth time.
The Falsified Medicines Directive (FMD), sets forth a number of measures to prevent the introduction of falsified medicines on the market. Thus, all packages of medicines that fall under this regulation must have a unique code and an anti-tampering device (ATD). On packages that do not fall under this obligation, marketing authorization holders can voluntarily attach an ATD. This information is now available in the online medicines database.